Cheng Cheng

This inventor holds 19 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Vaccine Development. Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Genzyme Corporation, Glaxosmithkline Biologicals Sa. Active years: 2009-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Cheng Cheng. Retrieved from https://idiyas.com/inventor/cheng-cheng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 7)

% Patents Active = 94.7

CIPO Patents = 1

EPO Patents = 8 (Patent Applications = 10)

Average Co-Inventor Count = 8.5

ph-index = 3

Forward Citations = 50(Granted Patents)

Location History:

Cambridge, MA (US) (2022)
Rockville, MD (US) (2009 - 2024)
Bethesda, MD (US) (2021 - 2024)

Company Filing History:

13 out of 3,699

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Glaxosmithkline Biologicals Sa

Janssen Vaccines & Prevention B.v.

Sabin Vaccine Institute

patent

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

Areas of Expertise:

HIV-1 Immunogens

Adenoviral Vectors

Nanoparticle Technologies

Filovirus Vaccines

Mammalian Cell Culture

Ebola Virus

Seneca Valley Virus

Recombinant Proteins

Glycan-Masked Domains

Self-Assembling Ferritin

Trimeric Antigens

Immunogenic Responses

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12486524 - Methods of culturing a mammalian cell (2025-12-02),

2. 12458691 - HIV-1 ENV fusion peptide immunogens and their use (2025-11-04),

3. 12145968 - Recombinant HIV-1 envelope proteins and their use (2024-11-19),

4. 12053520 - Glycan-masked engineered outer domains of HIV-1 gp120 and their use (2024-08-06),

5. 11939356 - Self-assembling insect ferritin nanoparticles (2024-03-26),

6. 11913013 - Chimpanzee adenoviral vector-based filovirus vaccines (2024-02-27),

7. 11602559 - HIV-1 Env fusion peptide immunogens and their use (2023-03-14),

8. 11459360 - Recombinant HIV-1 envelope proteins and their use (2022-10-04),

9. 11306341 - Methods of culturing a mammalian cell (2022-04-19),

10. 11235056 - Glycan-masked engineered outer domains of HIV-1 gp120 and their use (2022-02-01),

11. 11136356 - Recombinant HIV-1 envelope proteins and their use (2021-10-05),

12. 10961283 - Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens (2021-03-30),

13. 10584355 - Chimpanzee adenoviral vector-based filovirus vaccines (2020-03-10),

14. 10400015 - Recombinant HIV-1 envelope proteins and their use (2019-09-03),

15. 9701718 - Adenovirus serotype 26 and serotype 35 filovirus vaccines (2017-07-11),

Title: Innovations of Cheng Cheng in HIV-1 Research

Introduction

Cheng Cheng, a notable inventor based in Rockville, MD, has made significant contributions to the field of biomedical research, particularly in the development of therapies aimed at combating HIV-1. With an impressive portfolio of 16 patents, Cheng's innovative work focuses on recombinant HIV-1 envelope proteins and their use in generating immune responses to the virus.

Latest Patents

Among Cheng's latest patents, two stand out for their potential impact on HIV-1 treatment and prevention. The first patent focuses on recombinant HIV-1 envelope proteins and their use, specifically disclosing HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation. These products can elicit a therapeutically effective immune response against HIV-1 infection. The second patent highlights glycan-masked engineered outer domains of HIV-1 gp120 and their applications. This innovation includes methods of using the immunogens to prime immune responses in subjects, which may lead to effective treatments or preventive strategies against HIV-1.

Career Highlights

Throughout his career, Cheng Cheng has collaborated with esteemed organizations such as the United States of America as represented by the Secretary of the Department of Health and Human Services and GlaxoSmithKline Biologicals SA. His efforts in these organizations have led to groundbreaking discoveries and developments in the fight against HIV.

Collaborations

Cheng has worked alongside distinguished colleagues, including John R. Mascola and Yongping Yang. These collaborations have enriched his research initiatives and expanded the impact of his innovations in the scientific community.

Conclusion

Cheng Cheng's inventive contributions to HIV-1 research illustrate the profound importance of innovation in the biomedical field. With the potential of his patents to advance therapies, Cheng remains a vital figure in the ongoing battle against HIV-1, showcasing the significant role of inventors in improving global health outcomes.

Profile summary based on public USPTO records.